Understanding chemotherapy for treating rheumatoid arthritis: Key points to consider
Rheumatoid arthritis (RA) is a chronic autoimmune disorder that affects millions worldwide. In the management of this debilitating condition, disease-modifying anti-rheumatic drugs (DMARDs) play a crucial role. Contrary to popular belief, DMARDs are not chemotherapy when used to treat RA. They are prescribed at much lower doses and do not target cancer cells.
Methotrexate is a common DMARD medication used in RA treatment. Improvement in symptoms can be seen within 3-6 weeks of starting methotrexate treatment, with the full benefit typically not seen until after 12 weeks. Regular appointments with the doctor are recommended to check for signs of side effects, which may include less appetite, nausea, vomiting, rash, temporary hair loss (rare), mouth ulcers, fatigue, headache, among others. These can be managed with regular blood tests and adjustments to the dosage or switching to another medication.
Taking a folic acid supplement along with methotrexate can reduce the severity or prevent some of its side effects. For mild disease, other medications such as sulfasalazine may be appropriate and cause fewer potential side effects.
Cyclophosphamide and azathioprine are other DMARDs that doctors may use to treat severe complications of RA, such as vasculitis. Azathioprine works by suppressing the immune system and may be used for severe RA or in cases of serious organ complications.
Rheumatologists use DMARDs to treat RA because they block the actions of the immune cells that are attacking healthy joints, helping to prevent damage and slow down the progression of the disease. A variety of DMARDs are available, including sulfasalazine, hydroxychloroquine, leflunomide, etanercept, adalimumab, infliximab, golimumab, certolizumab pegol, tocilizumab, sarilumab, rituximab, tofacitinib, baricitinib, and upadacitinib.
It is important to note that the best DMARD medication may vary for each person with RA, and a combination of different DMARDs or another class of medication may be appropriate. Regular monitoring and adjustments are crucial to ensure the most effective and safe treatment.
The American Academy of Rheumatology recommends methotrexate as a first-line treatment for moderate-to-severe RA. Doctors consider methotrexate to be an effective treatment with typically minimal side effects.
Post-chemotherapy rheumatism, a type of inflammatory arthritis that can present like RA, can occur in some people who have cancer chemotherapy; however, it is not RA.
In summary, DMARDs are essential in the treatment of rheumatoid arthritis, helping to manage symptoms, prevent damage to joints, and slow down the progression of the disease. Regular monitoring, adjustments, and a personalised treatment plan are key to effective management of RA.
- Individuals diagnosed with rheumatoid arthritis (RA) may benefit from treatment with disease-modifying anti-rheumatic drugs (DMARDs), as these drugs play a crucial role in managing this chronic autoimmune disorder.
- Methotrexate is a common DMARD medication used in RA treatment, and it is often observed that improvement in symptoms can be seen within 3-6 weeks of starting methotrexate treatment.
- Regular appointments with the doctor are recommended for people on methotrexate treatment to check for signs of side effects, which may include less appetite, nausea, and temporary hair loss (though this is rare).
- In cases of mild RA, other medications such as sulfasalazine may be appropriate, causing fewer potential side effects compared to methotrexate.
- For severe complications of RA, cyclophosphamide and azathioprine are other DMARDs that doctors may use, such as when treating vasculitis.
- Rheumatologists use a variety of DMARDs to treat RA, including sulfasalazine, hydroxychloroquine, leflunomide, etanercept, adalimumab, infliximab, golimumab, certolizumab pegol, tocilizumab, sarilumab, rituximab, tofacitinib, baricitinib, and upadacitinib, each targeting different aspects of the immune response.
- It is important to note that the best DMARD medication may vary for each person with RA, and a combination of different DMARDs or another class of medication may be appropriate in individual cases. Regular monitoring and adjustments are crucial to ensure the most effective and safe treatment for each RA patient.
